miresearchreports
At Million Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.
 Market Segments 2025 by Application and Region)
Clinical Oncology Next Generation Sequencing (NGS) Market Segments 2025 by Application and Region
The global clinical oncology next generation sequencing (NGS) market size is expected to reach USD 1.5 billion by 2025, registering a CAGR of 13.2% over the forecast period. Rise in demand for personalized medicine, coupled with growth in next generation sequencing technology, is anticipated to accelerate the growth of NGS technology in clinical diagnostics.
Access Sample Report of this report @ https://www.radiantinsights.com/research/clinical-oncology-next-generation-sequencing-ngs-market/request-sample
Owing to the fact that next generation sequencing offers several advantages such as sensitivity, accuracy, and speed, this technology is anticipated to drive the oncology clinical diagnostics market. Furthermore, next generation sequencing aids in the assessment of multiple genes in a single assay, thereby eliminating the need to order several tests for determination of underlying mutation.
North America held the dominant share in the global the market for clinical oncology NGS in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate infrastructure in the healthcare industry. Asia Pacific is expected to be the fastest-growing regional market throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Presence of untapped markets in emerging economies in the region will also benefit regional growth.
Further key findings from the report suggest:
- By technology, targeted sequencing and resequencing held the largest share in 2018 owing to frequent usage in cancer diagnostics. On the other hand, whole-genome sequencing (WGS) is expected to grow at a lucrative rate owing to wide-scale applications and rising demand for the technique
- Based on application, companion diagnostics is anticipated to witness the fastest growth as a consequence of presence of a substantial number of pharmaceutical and diagnostic developers collaborating to commercialize the products. These participants are focused on extensive R&D in companion diagnostics to obtaining regulatory approval for novel assays combined with pharmaceuticals
- On the basis of end use, the clinics segment will expand at a significant growth rate thanks to increase in feasibility for the use of next generation sequencing technology
- North America occupied the largest share owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure
- Asia Pacific is expected to grow at the fastest rate due to continuous reforms in the healthcare and pharmaceutical sectors, accompanied by improvement in reimbursement policies
- Illumina, Inc.; Thermo Fisher Scientific; F. Hoffmann-La Roche Ltd; Agilent Technologies; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer; Foundation Medicine; Pacific Bioscience; Oxford Nanopore Technologies Ltd; Paradigm Diagnostics; Caris Life Sciences; Partek, Inc.; Eurofins Scientific S.E; and Qiagen N.V. are some of the key participants operating in this market. These participants are engaged in new product development and strategic alliances for enhancing their competitive footprint in the market.
Browse Full Report With TOC @ https://www.radiantinsights.com/research/clinical-oncology-next-generation-sequencing-ngs-market
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: sales@radiantinsights.com
